119 related articles for article (PubMed ID: 7315355)
21. The streptococcal preparation OK-432 specifically augments the susceptibility of human urinary bladder tumor cells to autologous peripheral blood lymphocytes.
Mizutani Y; Nio Y; Yoshida O
Cancer; 1992 Jun; 69(12):2999-3007. PubMed ID: 1591693
[TBL] [Abstract][Full Text] [Related]
22. [Immunologic indices of patients with transitional cell carcinoma of the urinary bladder].
Bkhatta AD; Makhlin NV
Urol Nefrol (Mosk); 1984; (2):67-70. PubMed ID: 6372193
[No Abstract] [Full Text] [Related]
23. Lack of specificity of lymphocyte-mediated cytotoxicity against the bladder cancer cell line, T24.
Catalona WJ; Oldham RK; Herberman RB; Djeu JY; Cannon GB
J Urol; 1977 Aug; 118(2):254-7. PubMed ID: 330885
[TBL] [Abstract][Full Text] [Related]
24. In vitro enhancement of natural killer cell activity by BCG and the antagonistic inhibition of the susceptibility of K562 cells to lysis by peripheral blood lymphocytes in patients with urinary bladder tumor.
Mizutani Y; Yoshida O
Int J Urol; 1994 Mar; 1(1):49-56. PubMed ID: 7627838
[TBL] [Abstract][Full Text] [Related]
25. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
26. Significance of cytotoxic activity of peripheral blood lymphocytes against autologous tumor cells in patients with bladder cancer.
Mizutani Y; Okada Y; Yoshida O; Bonavida B
Cancer Biother Radiopharm; 1996 Dec; 11(6):385-91. PubMed ID: 10851499
[TBL] [Abstract][Full Text] [Related]
27. Lymphocyte-mediated cytotoxicity in patients with renal and transitional cell carcinoma receiving BCG.
Lange PH
Natl Cancer Inst Monogr; 1978 Dec; (49):343-5. PubMed ID: 748791
[TBL] [Abstract][Full Text] [Related]
28. Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells.
Hermann GG; Petersen KR; Steven K; Zeuthen J
J Clin Immunol; 1990 Nov; 10(6):311-20. PubMed ID: 1707414
[TBL] [Abstract][Full Text] [Related]
29. In vitro generation of cytotoxic lymphocytes by tumor extracts of transitional cell carcinoma.
Morales A
Natl Cancer Inst Monogr; 1978 Dec; (49):173-4. PubMed ID: 748769
[TBL] [Abstract][Full Text] [Related]
30. Mixed leukocyte culture reactivity of lymph node cells regional to transitional cell carcinoma of the bladder.
Herr HW; Bean MA; Whitmore WF
Natl Cancer Inst Monogr; 1978 Dec; (49):177-81. PubMed ID: 155221
[TBL] [Abstract][Full Text] [Related]
31. Depression of the generation of cell-mediated cytotoxicity by macrophage-like suppressor cells in bladder carcinoma patients.
Spina CA; Dorey F; Vescera C; Brosman S; Fahey JL
Cancer Res; 1981 Nov; 41(11 Pt 1):4324-30. PubMed ID: 6458353
[TBL] [Abstract][Full Text] [Related]
32. Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing.
Pryor K; Goddard J; Goldstein D; Stricker P; Russell P; Golovsky D; Penny R
Br J Cancer; 1995 Apr; 71(4):801-7. PubMed ID: 7710947
[TBL] [Abstract][Full Text] [Related]
33. Lymphocyte antibody interaction in cytotoxicity against human transitional cell carcinoma.
Hakala TR; Lange PH; Castro AE; Elliott AY; Fraley EE
J Urol; 1975 May; 113(5):663-7. PubMed ID: 1168732
[TBL] [Abstract][Full Text] [Related]
34. Studies of the nonspecific cellular immune response in patients with urinary bladder carcinoma. I. PHA-induced lymphocyte transformation.
Nishio S; Horii A; Morikawa Y; Kawakita J; Nishijima T; Kishimoto T; Maekawa M
Invest Urol; 1979 Mar; 16(5):336-41. PubMed ID: 429127
[TBL] [Abstract][Full Text] [Related]
35. Disease-related lymphocyte cytotoxicity in rats bearing transitional cell carcinoma of bladder. Effect of immunomodulators.
Moroz C; Madgar I; Twig S; Lindner A; Many M
Int J Cancer; 1982 Jun; 29(6):667-72. PubMed ID: 6980847
[TBL] [Abstract][Full Text] [Related]
36. Changes in cell-mediated cytotoxicity during the clinical course of patients with bladder carcinoma.
Hakala TR; Lange PH; Elliott AY; Fraley EE
J Urol; 1976 Mar; 115(3):268-73. PubMed ID: 768528
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxicity of lymphocytes from patients with cancer of the urinary bladder: detection by a 3-H-proline microcytotoxicity test.
Bean MA; Pees H; FOGH JE; Grabstald H; Oettgen HF
Int J Cancer; 1974 Aug; 14(2):186-97. PubMed ID: 4477555
[No Abstract] [Full Text] [Related]
38. Immunosurveillance in pre-malignant occupational bladder disease.
Taylor G; Kumar S; Brenchley P; Wilson P; Costello B; Shaw GH
Int J Cancer; 1979 Apr; 23(4):487-93. PubMed ID: 86524
[TBL] [Abstract][Full Text] [Related]
39. Lymphoid cells mediating tumor-specific cytotoxicity to carcinoma of the urinary bladder. Separation of the effector population using a surface marker.
O'Toole C; Stejskal V; Perlmann P; Karlsson M
J Exp Med; 1974 Mar; 139(3):457-66. PubMed ID: 4591169
[TBL] [Abstract][Full Text] [Related]
40. Association between HLA antigens and bladder tumors.
Tokuç R; Akdaş A; Ozerkan K; Remzi D
Eur Urol; 1987; 13(3):207-9. PubMed ID: 3497040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
